Business · 15/03/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for OVIDREL Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for OVIDREL, a human drug product, in response to a patent extension application submitted to the US Department of Commerce
Original source language: Federal Register — Food and Drug AdministrationOpen original release →